|1.13||+0.0800||+7.62%||Vol 490.70K||1Y Perf -91.48%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||0.04 3.54%|
|Target Price||22.33||Analyst Rating||Moderate Buy 1.75|
|Potential %||1.88K||Finscreener Ranking||★★★★ 53.61|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 56.19|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 59.23|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||1.93||Earnings Rating||Strong Sell|
|Market Cap||61.56M||Earnings Date||13th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.50|
|EPS Growth Next 5 Years %||5.10|
|Avg. Weekly Volume||449.10K|
|Avg. Monthly Volume||451.20K|
|Avg. Quarterly Volume||565.43K|
Cara Therapeutics Inc. (NASDAQ: CARA) stock closed at 1.13 per share at the end of the most recent trading day (a 7.62% change compared to the prior day closing price) with a volume of 490.70K shares and market capitalization of 61.56M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Cara Therapeutics Inc. CEO is Derek T. Chalmers.
The one-year performance of Cara Therapeutics Inc. stock is -91.48%, while year-to-date (YTD) performance is -89.48%. CARA stock has a five-year performance of -92.97%. Its 52-week range is between 0.9 and 12.8, which gives CARA stock a 52-week price range ratio of 1.93%
Cara Therapeutics Inc. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 14.00, a price to cashflow ratio of 25.00, a PEG ratio of -1.25, a ROA of -43.80%, a ROC of -44.43% and a ROE of -49.13%. The company’s profit margin is 17.76%, its EBITDA margin is -227.00%, and its revenue ttm is $38.61 Million , which makes it $0.72 revenue per share.
Of the last four earnings reports from Cara Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Cara Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cara Therapeutics Inc. is Moderate Buy (1.75), with a target price of $22.33, which is +1 876.11% compared to the current price. The earnings rating for Cara Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cara Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.04, ATR14 : 0.11, CCI20 : 44.50, Chaikin Money Flow : -0.21, MACD : -0.08, Money Flow Index : 47.33, ROC : 2.73, RSI : 50.00, STOCH (14,3) : 88.46, STOCH RSI : 1.00, UO : 54.72, Williams %R : -11.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cara Therapeutics Inc. in the last 12-months were: Christopher A. Posner (Sold 5 987 shares of value $58 134 ), Frederique Menzaghi (Sold 16 034 shares of value $129 485 ), Goncalves Joana (Sold 18 220 shares of value $152 791 ), Joana Goncalves (Sold 18 489 shares of value $176 953 ), Menzaghi Frederique Ph.D. (Sold 2 993 shares of value $10 505 ), Posner Christopher (Sold 22 150 shares of value $142 465 ), Scott M. Terrillion (Sold 11 298 shares of value $101 790 ), Terrillion Scott (Sold 11 220 shares of value $81 642 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.